Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Value · T. Rowe Price

MassMutual Diversified Value Fund Class A (MDDAX)

Ticker MDDAX · · Holdings as of Jun 30, 2026

Expense ratio
1.1%$110/yr per $10k
5-yr return
+11.8%annualized
1-yr return
+10.3%as of Dec 2025
Net assets
$454.5Mall share classes
Holdings
224

Bottom line

Is MDDAX a good fund? The bottom line

MDDAX is the Class A share class of MassMutual Diversified Value Fund, a managed large value mutual fund from T. Rowe Price.

Annual fees run 1.1% — about $110 a year on every $10,000 invested, more expensive than 73% of large value funds we track.

It returned +10.3% over one year, +11.8% a year over five years, +10.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $455 million in net assets and 224 holdings, its largest position is JPMorgan Chase & Co (4.4%) and the top 10 make up 27.8% of the portfolio.

This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.

What stands out

  • Broadly diversified (224 holdings)

What to watch

  • Expensive for its category (1.1%)
  • Front-end sales load up to 5.5%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What MDDAX invests in

This Fund seeks to achieve long-term growth of capital and income by investing primarily in a diversified portfolio of equity securities of larger, well-established companies.

Principal Investment Strategies The Fund invests primarily in stocks of companies that the Funds subadviser, Brandywine Global Investment Management, LLC (Brandywine Global), believes are undervalued in the marketplace. While the Fund does not limit its investments to issuers in a particular capitalization range, Brandywine Global currently focuses on securities of larger size companies. The Fund normally invests at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in stocks, securities convertible into stocks, and other securities, such as warrants and stock rights, whose value is based on stock prices. The Fund typically invests most of its assets in securities of U.S. companies, but may invest up to 25% of its total assets in foreign securities and American Depositary Receipts (ADRs), including emerging market securities. The Fund may use…

From the fund's prospectus (filed Jan 30, 2026).

MDDAX performance

Average annual total returns
1 yr5 yr10 yr
MDDAX+10.3%+11.8%+10.2%
Large Value median+13.6%+11.3%+10.2%

Source: Fund prospectus, as of Dec 31, 2025

Full MDDAX performance history →

What MDDAX costs

On a $10,000 investment, MDDAX's 1.1% expense ratio costs about $110 a year. The prospectus estimates $1,816 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.

See the full MDDAX fee table →

MDDAX top 10 holdings

#Holding% of fund
1JPMorgan Chase & Co4.43%
2Johnson & Johnson3.80%
3Exxon Mobil Corp3.26%
4Apple Inc2.64%
5Morgan Stanley2.48%
6Goldman Sachs Group Inc/The2.35%
7iShares Russell 1000 Value ETF2.32%
8Microsoft Corp2.31%
9QUALCOMM Inc2.15%
10Bank of America Corp2.01%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 27.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to MDDAX

More funds like MDDAX →

MDDAX FAQ

What is the expense ratio of MDDAX?
MDDAX's expense ratio is 1.1%, which works out to about $110 a year for every $10,000 invested. The prospectus estimates total costs of $1,816 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MDDAX a good investment?
It depends on your goals, but the data points to: broadly diversified (224 holdings); expensive for its category (1.1%); front-end sales load up to 5.5%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does MDDAX hold?
MDDAX's largest holdings are JPMorgan Chase & Co (4.4%), Johnson & Johnson (3.8%), Exxon Mobil Corp (3.3%), Apple Inc (2.6%), Morgan Stanley (2.5%). It holds 224 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MDDAX's 5-year return?
MDDAX returned +11.8% a year over the five years ending Dec 31, 2025, and +10.2% a year over ten years. Past performance does not guarantee future results.
Does MDDAX have a sales load?
Yes. MDDAX has a maximum front-end sales charge of 5.5%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages MDDAX?
MDDAX is offered by T. Rowe Price through Massmutual Select Funds.